Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) EBIT (2016 - 2025)

Historic EBIT for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$55.6 million.

  • ImmunityBio's EBIT rose 3068.17% to -$55.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$260.7 million, marking a year-over-year increase of 2760.55%. This contributed to the annual value of -$344.2 million for FY2024, which is 498.77% up from last year.
  • ImmunityBio's EBIT amounted to -$55.6 million in Q3 2025, which was up 3068.17% from -$71.3 million recorded in Q2 2025.
  • ImmunityBio's EBIT's 5-year high stood at -$55.6 million during Q3 2025, with a 5-year trough of -$111.6 million in Q1 2023.
  • Its 5-year average for EBIT is -$83.1 million, with a median of -$84.9 million in 2022.
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 15666.65% in 2021, then surged by 3231.96% in 2025.
  • Quarter analysis of 5 years shows ImmunityBio's EBIT stood at -$79.3 million in 2021, then dropped by 7.1% to -$84.9 million in 2022, then dropped by 0.58% to -$85.4 million in 2023, then grew by 18.72% to -$69.4 million in 2024, then grew by 19.84% to -$55.6 million in 2025.
  • Its EBIT was -$55.6 million in Q3 2025, compared to -$71.3 million in Q2 2025 and -$64.4 million in Q1 2025.